MedTrace Logo

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 641

Last updated 2026-05-08

No results posted yet for this study

Summary

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Conditions

  • Non-Muscle Invasive Bladder Neoplasms

Interventions

COMBINATION_PRODUCT

TAR-210

TAR-210 will be administered intravesically.

DRUG

Gemcitabine

Gemcitabine will be administered intravesically.

DRUG

MMC

MMC will be administered intravesically.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation Inc. Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-18
Primary Completion
2028-06-28
Completion
2032-12-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • Brazil
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • Hong Kong
  • Ireland
  • Israel
  • Italy
  • Japan
  • Poland
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319820 on ClinicalTrials.gov